Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard Jon Barry
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Beta
- -0.70
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -7.27
Financials
FLNA has only 8 quarterly periods on file — the charts below show the full history available.
Net Income
$-8.60MEBITDA
$-9.09MFree Cash Flow
$-3.88MEPS (diluted)
$-0.18Shares Outstanding (diluted)
48.31M+0.7%Operating Expenses
$9.09MCash & Debt
$82.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-90.97M | $-1.88 |
| 2024 | $0.00 | $-24.34M | $-0.53 |
| 2023 | $0.00 | $-97.22M | $-2.32 |
| 2022 | $0.00 | $-76.25M | $-1.90 |
| 2021 | $0.00 | $-32.38M | $-0.82 |
Valuation
FLNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-54.55%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company's management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York.
View source ↗ - Newsbenzinga.com·17d ago·Negative
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).
View source ↗ - Newsglobenewswire.com·17d ago·Negative
…ader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's investigational new drug (IND) applicati…
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $-0.24 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.18 vs $-0.23beat
- Thu, May 7$-0.21 vs $-0.23beat
- Thu, Mar 12$-0.26 vs $-0.30beat
- Wed, Nov 12$-0.22 vs $-0.27beat
- Mon, Mar 3$-0.57 vs $-0.58beat
Estimates and results for FLNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in FLNA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.